<DOC>
	<DOCNO>NCT00497133</DOCNO>
	<brief_summary>Glucagon-like peptide 1 know improve sensitivity pancreatic beta-cell . Further inhibit secretion pancreatic alpha-cell mechanism fully understand . With study wish elucidate potential GLP-1 increase sensitivity alpha-cell . Type 2 diabetic patient control subject receive infusion GLP-1 increase dos saline , alpha- beta-cell response measure blood-samples . During study plasma-glucose level clamp fasting level . With study hope elucidate pathophysiology behind defect glucose tolerance type 2 diabetes mellitus potential GLP-1 treatment type 2 diabetes mellitus .</brief_summary>
	<brief_title>Alpha-Cell Sensitivity GLP-1 Patients With Type 2 Diabetes</brief_title>
	<detailed_description>Background : Glucagon-like peptide-1 ( GLP-1 ) possess insulinotropic glucagonostatic property , , therefore , GLP-based antidiabetic therapy develop . Even though insulinotropic potency GLP-1 show reduced patient type 2 diabetes mellitus ( T2DM ) , small dose GLP-1 capable normalize beta-cell responsiveness glucose patient . The glucagonostatic potency GLP-1 patient T2DM know , , furthermore , capability GLP-1 reestablish normal glucagon secretion patient remain elucidated . Objective : To investigate alpha-cell sensitivity GLP-1 patient T2DM establish GLP-1 able reestablish normal glucagon secretion patient . Method : Ten patient T2DM ten healthy control subject clamp fast blood glucose level GLP-1 infusion increase dos ( 0.25 , 0.5 , 1.0 2.0 pmol/kg/min ) placebo , respectively . Furthermore , patient hospitalize overnight receive intravenous insulin thereafter examine normoglycaemic condition . Blood drawn analysis plasma insulin , C-peptide , GLP-1 glucagon . Expected result conclusion : We expect GLP-1 inhibit glucagon secretion dose dependent manner , lead increase glucose turn-over . The result potentially elucidate interaction GLP-1 glucagon secretion thereby broaden knowledge pathophysiology T2DM . Furthermore , present study determine therapeutic impact GLP-1 alpha-cell deficiency characterize patient T2DM .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Informed oral write consent Caucasians age &gt; 18 year diagnose T2DM due WHO criteria . Normal haemoglobin HbA1c 610 % BMI 2335 kg/m2 Hepatic disease , ALAT &gt; 2 x normal . Diabetic nephropathy , ( Screatinine &gt; 130Î¼M albuminuria ) . Diabetic neuropathy ( report ) Proliferative diabetic retinopathy ( report ) Medical treatment pause 12 hour Insulin glitazon treatment</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>glucoseintolerance</keyword>
</DOC>